|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Calithera Biosciences, Inc. (CALA) |
|
|
$0.02 0.00 (0.00%) as of 4:30 Wed 4/24
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
97,237,000 |
| Market
Cap: |
1.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.015 - $0.365 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Calithera Biosciences is a clinical-stage precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Co.'s product candidate, CB-280, is an oral inhibitor of arginase, developed for the treatment of cystic fibrosis. Co. has also identified CB-668, an orally administered inhibitor of the immune-suppressive enzyme IL4I1. An additional arginase inhibitor, INCB001158, was discovered by Co. and is being developed by Incyte Corporation for oncology and hematology indications. Co. has developed CB-708, a selective, orally-bioavailable small molecule inhibitor of CD73.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
121,333 |
| Total Sell Value |
$0 |
$0 |
$0 |
$46,810 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2020-05-21 |
4 |
S |
$6.00 |
$13,701,588 |
D/D |
(2,283,598) |
480,432 |
|
42% |
|
| Wong Stephanie |
SR. VP, FINANCE & SECRETARY |
• – – |
2020-04-15 |
4 |
AS |
$8.00 |
$40,000 |
D/D |
(5,000) |
30,082 |
|
-49% |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2020-02-20 |
4 |
AS |
$8.00 |
$24,168 |
D/D |
(3,021) |
8,541 |
|
-31% |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-12-23 |
4 |
AS |
$6.00 |
$18,126 |
D/D |
(3,021) |
11,562 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-11-20 |
4 |
B |
$3.91 |
$750,847 |
D/D |
191,954 |
672,682 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-11-14 |
4 |
B |
$3.37 |
$433,005 |
D/D |
128,488 |
658,531 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-10-30 |
4 |
B |
$2.70 |
$2,153,272 |
D/D |
797,508 |
647,426 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-10-29 |
4 |
B |
$2.60 |
$4,157,340 |
D/D |
1,598,977 |
589,558 |
2.45 |
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2019-06-25 |
4 |
B |
$3.88 |
$200,208 |
I/I |
51,600 |
457,188 |
1.99 |
- |
|
| Molineaux Susan |
PRESIDENT AND CEO |
• • – |
2019-06-25 |
4 |
B |
$3.88 |
$200,208 |
I/I |
51,600 |
457,188 |
2.66 |
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2019-06-24 |
4 |
OE |
$0.96 |
$20,869 |
D/D |
21,739 |
72,057 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,526,004 |
|
- |
|
| Wong Stephanie |
SR. VP, FINANCE & SECRETARY |
• – – |
2019-06-19 |
4 |
OE |
$2.64 |
$26,400 |
D/D |
10,000 |
31,751 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-06-17 |
4 |
AS |
$6.00 |
$2,502 |
D/D |
(417) |
12,083 |
|
- |
|
| Parlati Francesco |
VP, RESEARCH |
• – – |
2019-06-17 |
4 |
OE |
$2.64 |
$16,489 |
D/D |
6,246 |
42,201 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-05-22 |
4 |
AS |
$6.00 |
$2,496 |
D/D |
(416) |
10,000 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-04-15 |
4 |
AS |
$6.33 |
$2,633 |
D/D |
(416) |
10,416 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-03-15 |
4 |
AS |
$6.43 |
$2,681 |
D/D |
(417) |
10,832 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2019-03-11 |
4 |
AS |
$6.00 |
$9,390 |
D/D |
(1,565) |
11,249 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2019-02-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
12,986 |
395,588 |
|
- |
|
| Molineaux Susan |
PRESIDENT AND CEO |
• • – |
2019-02-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
12,986 |
395,588 |
|
- |
|
| Molineaux Susan |
PRESIDENT AND CEO |
• • – |
2018-11-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
6,476 |
408,574 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2018-11-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
6,476 |
408,574 |
|
- |
|
| Orford Keith |
SR. VP, CLINICAL DEVELOPMENT |
• – – |
2018-10-15 |
4 |
AS |
$6.05 |
$1,894 |
D/D |
(313) |
10,314 |
|
- |
|
| Orford Keith |
SR. VP, CLINICAL DEVELOPMENT |
• – – |
2018-10-11 |
4 |
AS |
$6.00 |
$7,512 |
D/D |
(1,252) |
10,627 |
|
- |
|
141 Records found
|
|
Page 3 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
